Dr. Burt Adelman is presently Executive Vice President Research and Development and Chief Medical Officer at Dyax, located in Burlington MA. He joined Dyax in February of 2012. Dr. Adelman was born in New York City in 1952. After attending Trinity College, Hartford, Connecticut, he received his M.D. degree from Cornell University Medical College in 1976. Dr. Adelman served as House Officer and Medical Resident at the Peter Bent Brigham Hospital (now the Brigham and Women’s Hospital) and Harvard Medical School from 1976 through 1978. He completed his hematology fellowship at the Brigham in 1981. Dr. Adelman holds boards in internal medicine and hematology. From 1981 to 1984, he was a member of the Harvard Medical School faculty and an attending physician at the Brigham and Women’s Hospital. In 1984, Dr. Adelman joined the faculty of the Medical College of Virginia and became Chief of the Hematology and Oncology Division of the Department of Medicine at the Hunter Holmes McGuire Department of Veteran’s Affairs Medical Center in Richmond, Virginia. At both Harvard and the Medical College of Virginia, Dr. Adelman focused his research efforts in platelet activation, vascular thrombosis and mechanisms of platelet-vessel wall interaction. In 1991, Dr. Adelman joined Biogen in Cambridge, MA, then an early biotech firm, and rejoined the faculty at Harvard Medical School and the Hematology Division at the Brigham and Women’s Hospital. While at Biogen and subsequently Biogen Idec, Dr. Adelman held various positions including Medical Director, Vice President Regulatory Affairs, Executive Vice President of Research and Development and Executive Vice President of Portfolio Strategy. During this period, Dr. Adelman led development efforts for Angiomax (bivalarudin) for anticoagulation during angioplasty (sold by the Medicines Company), Avonex (interferon beta) for multiple sclerosis, Amevive (alefecept) for psoriasis, and Tysabri (natalizumab) for multiple sclerosis. Dr. Adelman’s experience and expertise in drug development spans from discovery to development to commercial promotion and includes biologics and small molecules. Dr. Adelman has worked in areas of autoimmune, neurological, oncologic and cardiovascular disease. Dr. Adelman retired from Biogen Idec in December 2007. During 2010, Dr. Adelman served as interim President of Research and Development at Eleven Biotherapeutics, a start-up biotechnology company. He is now senior advisor for Eleven. Currently, Dr. Adelman serves as a board member for the Maine Coast Heritage Trust, is a member of the Tufts Medical School Board of Overseers, an advisor to the Biomedical Research Institute at the Brigham and Women’s Hospital and is a member of the investment committee of the Partners Innovation Fund (Mass General and Brigham and Women’s Hospitals). Previous board of director roles includes the American Cancer Society (New England Region) and the New England Health Care Institute. Dr. Adelman is also a Visiting Scholar at the MIT Center for Biologic Innovation and a member of the Corporation of Partners Healthcare.